Mechanistically, HSD17B12 boosts anti-tumor immunity by facilitating VAC14-ESCRT-mediated degradation of PD-L1, independently of CMTM6, HIP1R, and palmitoylation. This evidence concerns the gene CD274 and neoplasm.